T (null )and M (null )genotypes of the glutathione S-transferase gene are risk factor for CAD independent of smoking by Abu-Amero, Khaled K et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
T null and M null genotypes of the glutathione S-transferase gene are 
risk factor for CAD independent of smoking
Khaled K Abu-Amero*1, Olayan M Al-Boudari1, Gamal H Mohamed2 and 
Nduna Dzimiri1
Address: 1Department of Genetics, King Faisal Specialist Hospital and Research Centre (MBC - 03), P. O. Box 3354, Riyadh 11211, Saudi Arabia 
and 2Department of Biostatics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Centre (MBC - 03), P. O. Box 
3354, Riyadh 11211, Saudi Arabia
Email: Khaled K Abu-Amero* - kamero@kfshrc.edu.sa; Olayan M Al-Boudari - olayan@kfshrc.edu.sa; 
Gamal H Mohamed - gmohamed@kfshrc.edu.sa; Nduna Dzimiri - dzimiri@kfshrc.edu.sa
* Corresponding author    
Abstract
Background: The association of the deletion in GSTT1 and GSTM1 genes with coronary artery
disease (CAD) among smokers is controversial. In addition, no such investigation has previously
been conducted among Arabs.
Methods: We genotyped 1054 CAD patients and 762 controls for GSTT1 and GSTM1 deletion
by multiplex polymerase chain reaction. Both CAD and controls were Saudi Arabs.
Results: In the control group (n = 762), 82.3% had the T wild M wildgenotype, 9% had the Twild M
null, 2.4% had the Tnull M wild and 6.3% had the Tnull M null genotype. Among the CAD group (n =
1054), 29.5% had the Twild M wild genotype, 26.6% (p < .001) had the Twild M null, 8.3% (p < .001) had
the Tnull M wild and 35.6% (p < .001) had the Tnull M null genotype, indicating a significant association
of the Twild M null, Tnull M wild and Tnull M null genotypes with CAD. Univariate analysis also showed
that smoking, age, hypercholesterolemia and hypertriglyceridemia, diabetes mellitus, family history
of CAD, hypertension and obesity are all associated with CAD, whereas gender and myocardial
infarction are not. Binary logistic regression for smoking and genotypes indicated that only M null
and Tnullare interacting with smoking. However, further subgroup analysis stratifying the data by
smoking status suggested that genotype-smoking interactions have no effect on the development
of CAD.
Conclusion: GSTT1 and GSTM1 null-genotypes are risk factor for CAD independent of genotype-
smoking interaction.
Background
Glutathione S-transferases (GSTs) are a group of enzymes
known to play an important role in the detoxification of
several endogenous and exogenous toxic and carcinogenic
substances [1]. In humans, GST enzymes are divided into
five subclasses: alpha (A), mu (M), pi (P), theta (T) and
zeta (z). In addition, each class includes several genes and
isoenzymes. GSTM1 products catalyze the conjugation of
glutathione to epoxide derivatives of polycyclic aromatic
hydrocarbons, the main carcinogens found in tobacco
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smoke. These products are important in the detoxification
of naturally occurring monohalomethanes, dichlo-
romethanes and ethylene oxides [1]. Polymorphisms in
the GSTT1 and GSTM1 genes are caused by a deletion,
which consequently results in virtual absence of enzyme
activity, especially in individuals with deletion in both
genes (null genotype). Many studies have demonstrated
great concordance (> 95%) between the genotype and
phenotype [2,3]. In experimental animals, chemicals in
tobacco smoke have been reported to induce and stimu-
late atherosclerotic plaque formation [4]. Thus, deletions
in the GSTT1 and GSTM1 genes affect the enzyme activity
possibly contributing to the development of coronary
atherosclerosis, especially among smokers [5-12]. The
association of the GSTT1 and GSTM1 null-genotypes with
coronary artery disease (CAD) among smokers has been
the subject of many investigations [5-12], but to our
knowledge no such studies have been conducted among
Arabs. Since 3 decades ago, the incidence of CAD has been
on the rise in Saudi Arabia. According to the biggest study
conducted in this regard so far in the kingdom, the overall
prevalence of CAD in Saudi Arabia is 5.5% [13]. This rise
has been attributed to the major changes in the life-style
of the Saudi population. High-fat diets, obesity, diabetes,
and smoking, all of which are considered CAD risk fac-
tors, have become more prevalent, and people are leading
a more sedentary lifestyle [14]. Therefore, our aim is to
investigate the possible relevance of the GSTM1 and
GSTT1 polymorphisms either individually or combined
(haplotype) on the development of CAD. The study will
also attempt to investigate the genotype-smoking interac-
tions and their potential effect on the development of
CAD in the presence or absence of other CAD risk factors.
Methods
Study population
The study group comprised 1054 individuals (642 males
with a mean age of 52 ± 7.5 yr and 412 females with a
mean age of 57 ± 7 yr) of Saudi Arabian descent with doc-
umented CAD, see Table 1 for demographic data on CAD
patients. The inclusion criteria comprised, among others,
the presence of angiographically determined narrowing of
the coronary vessels by at least 70%, and can be defined as
having severe disease. Exclusion criteria for CAD were cor-
onary artery bypass surgery or angioplasty within
3months of the study, major cardiac rhythm disturbances,
incapacitating or life-threatening illness, major psychiat-
ric illness or substance abuse, history of cerebral vascular
disease, neurological disorder, and administration of psy-
chotropic medication. Additionally, 762 individuals (464
males, mean age 53 ± 6.1 yr and 298 females, mean age
55 ± 3.2 yr) undergoing surgery for heart valve diseases or
receiving workups for cardiomyopathies and persons who
reported with chest pain, but were established to have
clear vessels by angiography, were recruited as controls
(CON) group. All our controls were strictly having clear
vessels by angiography. Exclusion criteria for this group
included among others diseases such as cancer, autoim-
mune disease, or any other disorders likely to interact with
variables under investigation. This study was performed
in accordance with the regulations laid down by the Hos-
pital Ethics Committee and all participants signed an
informed consent.
Sample collection, DNA extraction and determination of 
CAD risk factors
Five ml of peripheral blood were collected in EDTA tubes
from all participating individuals after obtaining their
Table 1: Demographic data and CAD risk factors distribution among anigiographed controls (CON) and CAD patients
CAD CON
Demographic data
No of patients 1054 762
Sex M 642 464
F 412 298
Mean age ± SD M 52 ± 7.5 y 53 ± 6.1 y
F 57 ± 7 y 55 ± 3.2 y
CAD risk factors
Family history (FH) of CAD 290 (27.5%) 162 (21.2%)
Obesity 723 (68.6%) 345 (45.3%)
Hypertriglyceridemia 616 (58.4%) 283 (37.1%)
Hypercholesterolemia 685 (65%) 307 (40.3%)
Diabetes Mellitus (DM) 592 (56.2%) 301 (39.5%)
Smokers 424 (40.2%) 114 (15%)
Hypertension 965 (91.5%) 497 (65.2%)
Myocardial infarction (MI) 103 (9.7%) 55 (7.2%)
DM, Diabetes Mellitus; FH, family history of CAD; MI, Myocardial infarction on admission; Hypertriglyceridemia (> 1.8 mmol/L); 
Hypercholesterolemia (> 5.2 mmol/L) and Obesity (Body Mass Index ≥ 30).BMC Medical Genetics 2006, 7:38 http://www.biomedcentral.com/1471-2350/7/38
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written consent. DNA extraction was performed using the
PURGENE DNA isolation kit from Gentra Systems (Min-
neapolis, USA), and stored in aliquots at -20°C until
required. Total serum cholesterol and triglyceride levels
were measured as routine in the main hospital pathology
laboratory on Konelab 20XTi clinical chemistry analyzer
utilizing specific kits according to the manufacturer's pro-
tocol. Calibration of the analyzer was performed daily
using internal controls prior to each session as per instruc-
tion of the manufacturer. Triglyceride levels > 1.8 mmol/
L and cholesterol levels > 5.2 mmol/L were considered
elevated. Diabetic patients either had a known history of
diabetes mellitus or were diagnosed as such according to
the American Diabetes Association criteria [15]. Individu-
als with body mass indices (BMI) ≥ 30 were considered
obese in accordance with the Center for Disease Control
and Prevention (Atlanta, GA, USA). Diagnosis of myocar-
dial infarction was based on the consensus specified by
the European Society of Cardiology and the American
College of Cardiology [16]. Information about all other
risk factors was procured either through patient interviews
or by referring to their medical records.
Detection of GSTT1 and GSTM1 deletions
Determination of the GSTT1 and GSTM1 deletions was
carried out by multiplex polymerase chain reaction (PCR)
amplification using the following primers: GSTT1 forward
primer 5'- TT CCT TAC TGG TCC TCA CAT CTC -3'; GSTT1
reverse primer 5'- TCA CCG GAT CAT GGC CAG CA -3';
GST M1 forward primer: 5'- GAA CTC CCT GAA AAG CTA
AAG C -3' and GSTM1 reverse primer 5'- GTT GGG CTC
AAA TAT ACG GTG G -3'. Each 25 µl PCR reaction con-
tained 2.5 µl of 10X reaction buffer with MgCl2 (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA), 10 ρ mol
of each primer, 100 ρ mol/µl each of deoxynucleoside tri-
phosphates (deoxyadenosine triphosphate, deoxyguanos-
ine triphosphate, deoxycytidine triphosphate and
deoxythymidine triphosphate) (Perkin-Elmer Corpora-
tion, Foster City, CA, USA) in Tris HCl buffer, 1 unit of
HotStar Taq DNA polymerase (Amersham Pharmacia Bio-
Table 2: Crude odds ratio for all CAD risk factors among CAD and CON groups
Risk factor Status CAD CON Odds ratio [95% C.I] p value
Genotype 
(haplotype)
Twild M wild 311 627 Reference - -
T1 and M1 genes Twild Mnull 280 69 8.17 6.01 – 11.1 < .001
Tnull Mwild 88 18 9.84 5.68 – 17.2 < .001
Tnull Mnull 375 48 15.7 11.2 – 22.2 < .001
Genotype (T1 
gene)
T wild 591 696 Reference - -
T null 463 66 8.26 6.19 – 11.05 < .001
Genotype (M1 
gene)
M wild 399 645 Reference - -
M null 655 117 9.05 7.12 – 11.5 < .001
Smoking No 630 648 Reference - -
Yes 424 114 3.83 3.01 – 4.87 < .001
Age < 40 172 165 Reference - -
≥ g40 882 597 1.42 1.11 – 1.81 .004
Hypercholesterole
mia
No 369 455 Reference - -
Yes 685 307 2.71 2.27 – 3.34 < .001
Hypertriglyceride
mia
No 438 479 Reference - -
Yes 616 283 2.38 1.97 – 2.89 < .001
DM No 462 461 Reference - -
Yes 592 301 1.96 1.62 – 2.37 < .001
FH No 764 600 Reference - -
Yes 290 162 1.40 1.13 – 1.75 .002
Gender F 412 298 Reference - -
M 642 464 1.0 0.82 – 1.22 .1
Hypertension No 89 265 Reference - -
Yes 965 497 5.77 4.41 – 7.59 < .001
Obesity No 331 417 Reference - -
Yes 723 345 2.64 2.17 – 3.22 < .001
MI No 951 707 Reference - -
Yes 103 55 1.39 0.98 – 1.99 .067BMC Medical Genetics 2006, 7:38 http://www.biomedcentral.com/1471-2350/7/38
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tech, Piscataway, NJ, USA) and 100 ng genomic DNA tem-
plate at annealing temperature of 58°C for 40 cycles. The
PCR products were visualized on a 2% agarose gel electro-
phoresed at 100V for 50 minutes. Two bands of 459 for
GSTT1 and 209 bp for GSTM1 were obtained for the Twild
M wild genotype. The Twild M null genotype showed only one
band of 459 bp and T null M wild a band of 209 bp. For T null
M null genotype (homozygous absence or deletion geno-
type is designated as null genotype) no bands were
obtained, necessitating the use of β-globin as internal pos-
itive control, in order to distinguish the null genotype
from aborted PCR reactions.
Statistical analysis
Genotype frequencies in both groups were compared by
Chi-Square test. Multivariable logistic regression was used
to study the effect of the GSTT1 and GSTM1 genotypes on
CAD, incorporating other variables (CAD risk factors)
into the model. A two-tailed p value <.05 was considered
statistically significant and odds ratio with 95% confi-
dence intervals are reported. All analyses were performed
using SPSS v.10 (SPSS Inc., Chicago, USA) statistical anal-
ysis software.
Results
Univariate analysis showed that the following variables
were associated with the manifestation of CAD: GSTT1
genotype (p < .001), GSTM genotype (p < .001), haplotype
GSTT1 plus GSTM1 (p  < .001), smoking, age, elevated
cholesterol and triglycerides, diabetes mellitus (DM),
family history of CAD (FH), hypertension and obesity,
whereas gender (p = .1) and myocardial infarction (MI)
on admission (p = .067) were not. The variables showing
an association (p < .05) in Table 2 were then put into a
stepwise multiple logistic regression, in order to study the
possible combined effect of the GSTT1 plus GSTM1 hap-
lotype with other risk factors on CAD manifestation. The
variables Tnull Mnull genotype, Twild Mnull genotype, Tnull
Mwild genotype, obesity and hypertension were retained in
the model were (Table 3), whereas the interaction of the
haplotype Tnull Mnull with smoking was not. Because of
this, we decided to carry out a multiple stepwise logistic
regression with each genotype separately. We first entered
the GSTT1 genotype (variable) with other CAD risk factors
into analysis. The only variables retained in the model
then were genotypes, hypertension, hypercholestero-
lemia, obesity and smoking (Table 4). The interaction
between smoking and genotypes with other CAD risk fac-
tors was not retained. We then entered the GSTM1 geno-
type (variable) into a stepwise multiple logistic regression
with CAD risk factors, resulting in the retention of the gen-
otype, hypertension, elevated cholesterol, obesity, smok-
ing and genotype-smoking interaction (Table 5).
The results for binary logistic regression model for smok-
ing and GSTM1 genotype (variable) alone (with no CAD
risk factors involved) were positive. Similar observations
were made for the GSTT1 genotype and smoking, indica-
tive of an interaction between these two genotypes and
smoking. This significance was however lost, when we
entered the GSTT1 genotype × smoking jointly with other
CAD risk factors (Table 4), but retained when we entered
the GSTM1 genotype × smoking jointly with other CAD
risk factors (Table 5).
Table 3: Results of stepwise multiple logistic regression analysis for the GSTM1 and GSTT1 haplotype: final significant variables in the 
model
Risk Factor (variables) Odds ratio [95% C.I] p value
Twild Mnull 8.90 6.36 – 12.5 < .001
Tnull Mwild 14.1 7.70 – 25.6 < .001
Tnull Mnull 17.7 12.4 – 25.3 < .001
Obesity 2.32 1.75 – 3.08 < .001
Hypertension 2.43 1.68 – 3.53 < .001
Table 4: Results of stepwise multiple logistic regression analysis for the GSTT1 genotype (variable): final significant variables in the 
model
Risk Factor (variables) Odds ratio [95% C.I] pvalue
GSTT1 Genotype (Twild vs. Tnull) 6.24 4.49 – 8.67 < .001
Hypertension 3.11 2.19 – 4.44 < .001
Hypercholesterolemia 1.57 1.22 – 2.02 < .001
Obesity 2.10 1.61 – 2.73 < .001
Smoking 1.96 1.45 – 2.64 < .001
GSTT1 genotype × smoking interaction was entered jointly into the multiple logistic regression analysis. Other factors were entered disjointedly. 
After analysis, the genotype × smoking interaction was not retained in the model and therefore is not shown in the above table.BMC Medical Genetics 2006, 7:38 http://www.biomedcentral.com/1471-2350/7/38
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Since we found significant interaction for smoking with
the genotype, we proceeded to stratify the data based on
smoking status. Although the GSTT1 genotype-smoking
interaction was not significant in the multivariate analysis
(Table 4), we included it nonetheless for consistency,
especially since smoking and this interaction had shown
significant association with CAD. In the subgroup analy-
sis, we found a significant difference between the CAD
and CON groups in the distribution of the Tnull among
smokers [odds ratio = 4.4; 95% CI (2.7–6.9); p < .001] and
non-smokers [odds ratio = 8.1; 95% CI (5.3–12.6); p <
.001]. Similarly, the prevalence of the Mnull among smok-
ers [odds ratio = 5; 95% CI (3.2–7.9); p < .001] and non-
smokers [odds ratio = 8.7; 95% CI (6.4–11.9); p < .001]
also exhibited significant difference between the groups
(Table 6).
Discussion
This study provided us with an excellent opportunity to
explore the effects of gene polymorphisms, gene-gene and
genotype – cigarette smoking interactions, as well as its
possible effect on the development of CAD. To our knowl-
edge, this is the first study to evaluate the prevalence of the
GSTT1 and GSTM1 gene polymorphisms in an Arab pop-
ulation. Among our angiographed controls, the GST M null
frequency was 0.153, which is lower than the values of
0.527, 0.550, 0.513, 0.497, 0.240, 0.299 observed among
Australians, Brazilians, Canadians, Chinese, Indians and
Black Americans [17] respectively. Also, the GST Tnull fre-
quency in this group was 0.09, which is lower than the
values of 0.184, 0.185, 0.172, 0.467, 0.182 and 0.231
observed among Australians, Brazilians, Canadians, Chi-
nese, Indians and Black Americans [5,17]. However, we
were unable to determine whether these polymorphisms
were in Hardy-Weinberg equilibrium, because hetero-
zygous individuals could not be distinguished from
homozygous wild type. Besides, it would be difficult for
us to test for the equilibrium, since random mating in the
Saudi population is not satisfied because of the high con-
sanguinity rate (> 65%) [18]. We can not offer a good
explanation, other than ethnicity-based variations, as to
why the prevalence rates of these two genotypes are lower
in our population, especially since our study involved a
reasonably large number of controls.
The univariate analysis showed that the genotypes Tnull
and Mnull, the haplotype Tnull plus Mnull, as well as smok-
ing, age, elevated cholesterol and triglycerides, diabetes,
family history of CAD, hypertension and obesity were
associated with CAD, whereas gender and myocardial inf-
arction were not. Surprisingly, myocardial infarction on
admission was not associated with CAD (p = .067), possi-
bly due to the small number of CAD patients with this dis-
order (9.8%). The association of the GST Tnull genotype,
Table 5: Results of stepwise multiple logistic regression analysis for the GSTM1 genotype (variable): final significant variables in the 
model
Risk Factor (variables) Odds ratio [95% C.I] pvalue
GSTM1 Genotype (Mwild vs. Mnull) 8.90 6.32 – 12.5 < .001
Hypertension 2.49 1.74 – 3.57 < .001
Hypercholesterolemia 1.39 1.10 – 1.81 .015
Obesity 2.10 1.59 – 2.75 < .001
Smoking 2.82 1.87 – 4.28 < .001
Genotype (Mwild vs. Mnull) × 
smoking
0.469 0.26 – 0.85 .012
GSTM1 genotype × smoking interaction was entered jointly into the multiple logistic regression analysis. Other factors were entered disjointedly. 
After analysis, the genotype × smoking interaction was retained in the model and therefore is shown in the above table.
Table 6: Distribution of genotypes among smokers and non-smokers
Risk factor Status CAD CON Odds ratio [95% C.I] p value
Smokers Twild 137 77 Reference - -
Tnull 287 37 4.4 2.7 – 6.9 < .001
Non-smokers Twild 456 619 Reference - -
Tnull 174 29 8.1 5.3 – 12.6 < .001
Smokers Mwild 84 63 Reference - -
Mnull 340 51 5 3.2 – 7.9 < .001
Non-smokers Mwild 317 582 Reference - -
Mnull 313 66 8.7 6.4 – 11.9 < .001
Wild, deletion is not present; Null, deletion is present.BMC Medical Genetics 2006, 7:38 http://www.biomedcentral.com/1471-2350/7/38
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Mnull  genotype, Tnull  plus Mnull  haplotype with CAD
observed in our study was not in concordance with the
finding of Girisha et al [5], who found no association of
the GST Mnull genotype with CAD in North Indian popu-
lation. Also, Wilson et al [10] reported that the GST Mnull
genotype was not significantly associated with the inci-
dence of CAD among South Asians. On the other hand,
our finding of an association of the GST Tnull genotype
with CAD was in agreement with the report by Tamer et al
[6], but not with other previous studies [5,8,10], which
did not find an association.
Our multivariate analysis indicated that genotypes Tnull,
Mnull and haplotype Tnull plus Mnull are strongly associated
with CAD in the presence of some CAD risk factors. How-
ever, the interaction of smoking with genotype was only
significant in case of the GSTM1 genotype, and this may
be because GSTM1 products are more directly involved
than GSTT1 in the detoxification of the main carcinogen
found in the tobacco smoke. However, when we studied
the prevalence of the Tnull and Mnull genotypes among
smokers and non-smokers with and without CAD, we
found a significant association with CAD among smokers
and non-smokers, with a stronger relation among non-
smokers. Thus, our results indicate significant relevance of
these two genotypes for the development of CAD, inde-
pendent of the smoking status. This finding is in agree-
ment with the studies by Wilson et al [10] and Wang et al
[19] and discordant with those of Tamer et al [6] and
Masetti et al [8], thus pointing to ethnic variability.
Our findings of significant relevance of these two geno-
types for the development of CAD, independent of the
smoking status might not be surprising. GST enzymes,
beside their role in detoxifying polycyclic aromatic hydro-
carbons found in tobacco smoke, involve in detoxifica-
tion of many chemical carcinogens, environmental
pollutants and anti-tumor agents. In addition, GST
enzymes inactivate endogenous unsaturated aldehydes,
quinines, epoxides and hydroperoxides formed as second-
ary metabolites during the oxidative stress [20]. GST
enzymes also play a key role in protecting blood vessels
against endogenous oxidants [20]. Therefore, absence of
or reduced GST enzyme activities may lead to malfunction
in the inactivation of these metabolites, generated during
the oxidative stress process, and this may contribute to the
development of atherosclerotic CAD. This indicates that
the presence of these deletion alleles (Mnull and Tnull) may
compromise one's capabilities for detoxification of differ-
ent endogenous and exogenous oxidants, other than
those found in cigarette smoke, and ultimately put one at
higher risk of developing CAD, even if one is not a
smoker.
Conclusion
We can conclude the following from this study: i) smok-
ing, Tnull and Mnull genotypes are independent risk factors
for CAD and ii) there is evidence of genotype-smoking








FH Family history of CAD
MI Myocardial infarction
PCR Polymerase chain reaction
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